423 related articles for article (PubMed ID: 24573550)
21. Mitogen-activated protein kinase pathway is pivotal for anoikis resistance in metastatic hepatoma cells.
Cao L; Zhang Z; Han L; Du J; Liang X; Liu Y; Sun W
Mol Med Rep; 2014 Apr; 9(4):1121-7. PubMed ID: 24535322
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Gu FM; Li QL; Gao Q; Jiang JH; Huang XY; Pan JF; Fan J; Zhou J
World J Gastroenterol; 2011 Sep; 17(34):3922-32. PubMed ID: 22025881
[TBL] [Abstract][Full Text] [Related]
23. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
24. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma.
Yang R; Piperdi S; Gorlick R
Clin Cancer Res; 2008 Oct; 14(20):6396-404. PubMed ID: 18927278
[TBL] [Abstract][Full Text] [Related]
25. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H
J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
[TBL] [Abstract][Full Text] [Related]
26. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
Salerno P; De Falco V; Tamburrino A; Nappi TC; Vecchio G; Schweppe RE; Bollag G; Santoro M; Salvatore G
J Clin Endocrinol Metab; 2010 Jan; 95(1):450-5. PubMed ID: 19880792
[TBL] [Abstract][Full Text] [Related]
27. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis.
Huynh H; Nguyen TT; Chow KH; Tan PH; Soo KC; Tran E
BMC Gastroenterol; 2003 Aug; 3():19. PubMed ID: 12906713
[TBL] [Abstract][Full Text] [Related]
28. Signaling pathways in hepatocellular carcinoma.
Sia D; Villanueva A
Oncology; 2011; 81 Suppl 1():18-23. PubMed ID: 22212931
[TBL] [Abstract][Full Text] [Related]
29. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB
Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
[TBL] [Abstract][Full Text] [Related]
30. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
31. Glabridin arrests cell cycle and inhibits proliferation of hepatocellular carcinoma by suppressing braf/MEK signaling pathway.
Wang Z; Luo S; Wan Z; Chen C; Zhang X; Li B; Huang G; Chen L; He Z; Huang Z
Tumour Biol; 2016 May; 37(5):5837-46. PubMed ID: 26586395
[TBL] [Abstract][Full Text] [Related]
32. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.
Nörz D; Grottke A; Bach J; Herzberger C; Hofmann BT; Nashan B; Jücker M; Ewald F
Cell Signal; 2015 Nov; 27(11):2191-200. PubMed ID: 26210887
[TBL] [Abstract][Full Text] [Related]
33. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway.
Okano J; Nagahara T; Matsumoto K; Murawaki Y
Basic Clin Pharmacol Toxicol; 2008 Jun; 102(6):543-51. PubMed ID: 18346049
[TBL] [Abstract][Full Text] [Related]
34. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.
Huynh H; Soo KC; Chow PK; Tran E
Mol Cancer Ther; 2007 Jan; 6(1):138-46. PubMed ID: 17237274
[TBL] [Abstract][Full Text] [Related]
35. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Li J; Shi L; Zhang X; Sun B; Yang Y; Ge N; Liu H; Yang X; Chen L; Qian H; Wu M; Yin Z
Oncotarget; 2016 Jan; 7(3):2646-59. PubMed ID: 26544731
[TBL] [Abstract][Full Text] [Related]
36. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.
Tong X; Wang Q; Wu D; Bao L; Yin T; Chen H
Biochem Biophys Res Commun; 2020 Feb; 523(1):147-152. PubMed ID: 31836141
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
38. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Gilmartin AG; Bleam MR; Groy A; Moss KG; Minthorn EA; Kulkarni SG; Rominger CM; Erskine S; Fisher KE; Yang J; Zappacosta F; Annan R; Sutton D; Laquerre SG
Clin Cancer Res; 2011 Mar; 17(5):989-1000. PubMed ID: 21245089
[TBL] [Abstract][Full Text] [Related]
39. MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.
Bessard A; Frémin C; Ezan F; Coutant A; Baffet G
J Cell Physiol; 2007 Aug; 212(2):526-36. PubMed ID: 17427199
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]